Tumour markers in cancers of unknown primary: A clinical perspective

Annals of Clinical Biochemistry

Volumn 43, Issue 1, 2006, Pages 1-2

  Savage, Philip ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; TUMOR MARKER;

BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY; CANCER SURVIVAL; CHORIOCARCINOMA; CHROMOSOME 12P; DISEASE MARKER; EDITORIAL; EVIDENCE BASED MEDICINE; GERM CELL TUMOR; HUMAN; ONCOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SERUM; SURVIVAL RATE; TESTIS CANCER;

HUMANS; NEOPLASMS, UNKNOWN PRIMARY; TUMOR MARKERS, BIOLOGICAL;

EID: 30844469064     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456306775141678     Document Type: Editorial

References (13)

1. Le Chevalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-9
2. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403-10
3. Kirsten F, Chi CH, Leary JA, Ng AB, Hedley DW, Tattersall MH. Metastatic adeno or undifferentiated carcinoma from an unknown primary site - natural history and guidelines for identification of treatable subsets. Q J Med 1987; 62: 143-61
4. Briasoulis E, Tolis C, Bergh J, Pavlidis N, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005; 16(Suppl. 1): i75-6
5. Loi S, Haydon AM, Shapiro J, Schwarz MA, Schneider HG. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital. Intern Med J 2004; 34: 545-50
6. Bosl GJ, Geller NL, Cirrincione C, et al. Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. Am J Med 1983; 75: 29-35
7. Bosl GJ, Ilson DH, Rodriguez E, Motzer RJ, Reuter VE, Chaganti RS. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86: 349-355
8. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13: 274-82
9. Barth JH, Jones RG. Indiscriminate investigations have adverse effects. Br Med J 2003; 326: 393
10. Sturgeon C. Practice Guidelines for tumor marker use in the Clinic. Clin Chem 2002; 48: 1151-9
11. Pavlidis N, Kalef-Ezra J, Briassoulis E, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22: 162-7
12. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004; 66: 293-6
13. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-93